CSO and co-founder of @ArsenalBio via @DanaFarber, @broadinstitute, and @Merck. He/his.
Boston, MA
Joined October 2009
- Tweets1.3K
- Following1.1K
- Followers3.2K
- Likes2.1K
I’m lucky that I get to work with this team.
We are excited to announce our $325 million #SeriesC financing. This new investment will enable ArsenalBio's ongoing development efforts and scale our manufacturing capabilities to develop T-cell medicines. We thank the new investors along with our existing investors for their support in helping us to achieve our goal to defeat cancer. #celltherapy #patientsfirst
arsenalbio.com/2024/09/04/ar…
Nick Haining retweeted
Proud to be one of said Braniacs! Looking forward to discussing our exciting work at #AACR2023
There’s some really awesome science going on at @ArsenalBio — come and meet the brainiacs building tomorrow’s cell therapy today at #AACR23 businesswire.com/news/home/2…
There’s some really awesome science going on at @ArsenalBio — come and meet the brainiacs building tomorrow’s cell therapy today at #AACR23 businesswire.com/news/home/2…
Well deserved award to a thoughtful and original scientist who has helped us all understand a lot about how T cells work and don’t work. Congrats @EJohnWherry !
We congratulate @EJohnWherry, of @PennMedicine on being recognized with the 2023 AACR-CRI Lloyd J. Old Award in Cancer Immunology. Learn more: bit.ly/40qAhnB @CancerResearch
I’m so glad this experiment ended and was reported in my lifetime. Amazing.
Authored by Andrew G. Soerens et al, we show that #Tcells are capable of proliferating in response to iterative stimulation for over 10yrs! And produce enough progeny to occupy a volume 30,000x the Earth's volume! @Nature nature.com/articles/s41586-0…
Nick Haining retweeted
Authored by Andrew G. Soerens et al, we show that #Tcells are capable of proliferating in response to iterative stimulation for over 10yrs! And produce enough progeny to occupy a volume 30,000x the Earth's volume! @Nature nature.com/articles/s41586-0…
Four years ago, the founders had a bunch of ideas on a whiteboard and not much else. Today, @ArsenalBio has dosed the first patient with AB-1015, an engineered autologous T cell therapy for ovarian cancer. Incredibly proud of what the Arsenal team has accomplished. Onwards.
The first patient has been dosed with AB-1015 in a Phase 1, first-in-human clinical trial for patients with ovarian cancer that is resistant to platinum-based regimens. It is our first internally discovered T cell medicine to enter clinical development: shorturl.at/iwT03
Go Deb go! Well deserved award to @DebattamaSen We’re going to learn a lot about the wiring of T cells from the Sen lab.
Early-stage investigators proposed innovative high-impact research ideas for the @NIHDirector’s New Innovator Award. See the projects the awardees will pursue: bit.ly/hrhr2022nia #NIHHighRisk
ALT Collage of the 2022 NIH Director's New Innovator Awardees.
Nick Haining retweeted
Our latest paper is out in @NatImmunol. This work represents a years-long effort from @dubrot_j Peter Du, @kathleenbyates @sarahkatelr and others to identify immune evasion genes using in vivo #CRISPRscreens in mouse cancer models treated with ICB. rdcu.be/cWcrJ
Delighted for the opportunity to collaborate with the rockstar team at Genentech and deploy Arsenal's tech stack to solve the biggest challenges in T cell therapy. This is going to be a lot of fun.
ArsenalBio will receive $70 million for a multi-year collaboration with Genentech to deploy ArsenalBio’s proprietary technology for high-throughput screening and engineering of T-cells to advance next-generation cell therapies for cancer. lnkd.in/ggcVFqqu #genentech
Grateful for this opportunity to keep raising the bar for better engineered T cell therapies for patients with cancer. Can't wait to share what we're building. @ArsenalBio fiercebiotech.com/biotech/bm…
Cogent analysis of decision-making around Covid boosters.
What should you do about COVID vaccine boosters? Should you wait until the fall for a BA.4/5 version? How often can you get boosted? A few thoughts here: medpagetoday.com/opinion/sec…
Having just spent 3 days at a #PICINetwork retreat, I think some of the most exciting and innovative work was presented by the scholars/early career scientists. The “kids” are alright.
This quoted post is unavailable.
Nick Haining retweeted
Our CEO @KDrazan, MD, was featured in @_CellandGene this morning! Hear Ken’s take on ArsenalBio’s pioneering approach and role in the future of engineering CAR-T #celltherapies in the Q&A by @ErinHarris_1 here:
cellandgene.com/doc/computat… #EngineeredToCure
Regardless about the generalizability of this finding I remain a firm proponent of snack-time.
We tend to schedule our day ignoring that the times are not the same. For a judge, parole rulings were found to be dependent on the time of day: a prisoner had nearly a 0% chance of getting parole just before lunch, but 65% for parole right after lunch. pnas.org/content/108/17/6889
